{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.6","upperLimit":"35.2","value":"24.1"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"6.3","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"DoR was defined as the time from date of first documented response of CR or PR to the date of first documented PD (per RECIST 1.1) or death due to any cause, whichever occurred earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"FAS included all randomized participants. Participants with confirmed CR or PR only are reported here.","reportingStatus":"POSTED","timeFrame":"Up to 73.5 months","title":"Duration of Response (DoR) Per IRC","type":"SECONDARY","unitOfMeasure":"months"}